Global Bipolar Depression Market Overview, Epidemiology and Market Forecast 2030 – ResearchAndMarkets.com | Company

DUBLIN – (BUSINESS WIRE) – August 3, 2021–

The report “Bipolar Depression – Market Overview, Epidemiology and Market Forecast – 2030” has been added to the offering of ResearchAndMarkets.com.

This “Bipolar Depression – Market Overview, Epidemiology, and Market Forecast – 2030” report provides an in-depth understanding of bipolar depression, historical and predicted epidemiology as well as bipolar depression market trends in the United States, in EU5 (Germany, France, Italy, Spain and United Kingdom) and Japan.

Epidemiology of bipolar depression

The Bipolar Depression Epidemiology division provides information on the historical and current pool of patients with bipolar depression and forecast trends for all seven major countries. It helps to recognize the causes of current and forecast trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the pool of patients diagnosed and their trends as well as the assumptions made.

Main conclusions

In 2020, the total number of prevalent cases diagnosed with bipolar depression was 3,552,076 cases in 7MM, which is expected to increase during the study period, i.e. 2017-2030.

Bipolar Depression Market Outlook

Currently, antipsychotics are the cornerstone of treatment for bipolar depression. Although patients with MB spend more time in depression than in mania or hypomania, only four drugs, all of which are antipsychotics, have been approved by the US FDA. The olanzapine-fluoxetine (OFC) combination was first approved in 2003; Quetiapine was approved in 2006.

In 2013, lurasidone was approved as monotherapy and as an addition to ongoing lithium or valproate for bipolar I depression. The fourth, cariprazine, a new second generation antipsychotic (SGA), was approved in 2019. Cariprazine joins quetiapine as the second FDA approved SGA for mania and depression, but has significant metabolic side effects advantages over quetiapine. Therapies approved in the 7MM include Vraylar (Cariprazine) and Latuda (Lurasidone Hydrochloride), among others.

Right now, some companies have started clinical trials that are investigating new treatment options. Key players such as Intra-Cellular Therapies (Caplyta, also known as Lumateperone), NeuroRx (NRX-100 / NRX-101), Sunovion (Sumitomo Dainippon Pharma) (SEP-4199), Lundbeck / Otsuka Pharmaceutical (Rexulti / Rxulti, also known as Brexpiprazole), COMPASS Pathways (COMP 360, also known as psilocybin therapy), Celon Pharma (Falkieri) and several others are studying their candidates for the management of bipolar depression in the 7MM.

Main topics covered:

1. Key information

2. Presentation of the report

3. Bipolar Depression Market Overview at a Glance

3.1. Market share (%) Distribution of bipolar depression in 2017

3.2. Market share (%) Distribution of bipolar depression in 2030

4. Executive summary of bipolar depression

5. Epidemiology and market methodology

6. Background and overview of the disease

6.1. introduction

6.2. Difference between bipolar and unipolar depression

6.3. Classification of comics according to DSM-5

6.4. Signs and symptoms

6.5. Causes

6.6. Risk factors

6.7. Pathophysiology

6.8. Genetic results in BD

6.9. Biomarkers

7. Diagnosis of bipolar disorder

7.1. Diagnostic criteria for the main forms of TB

7.1.1. Diagnosis to rule out thyroid disorders

7.2. Differential diagnosis

7.3. Diagnostic guidelines

7.3.1. Evidence-Based Guidelines for the Treatment of Bipolar Disorder: Revised Recommendations from the Third Edition of the British Association for Psychopharmacology Guidelines

7.3.2. National Institute for Health and Care Excellence (NICE) guidelines for diagnosing bipolar disorder

8. Current therapeutic practices for bipolar disorder

8.1. Treatment of bipolar disorder

8.1.1. Processing algorithm

8.2. Treatment guidelines

8.2.1. World Federation of Biological Psychiatric Societies (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorder: 2010 Update on the Treatment of Acute Bipolar Depression

8.2.2. World Federation of Biological Psychiatric Societies (WFSBP) guidelines for the biological treatment of bipolar disorder: 2012 update on the long-term treatment of bipolar disorder

8.2.3. American Psychiatric Association Practice Guidelines for the Treatment of Bipolar Disorder

8.2.4. National Institute for Health and Care Excellence (NICE) guidelines for the treatment of bipolar disorder

8.2.5. Evidence-Based Guidelines for the Treatment of Bipolar Disorder: Revised Recommendations from the Third Edition of the British Association for Psychopharmacology

8.2.6. Guideline for Treatment of Bipolar Disorder by the Japanese Mood Disorders Society, 2012

8.2.7. Clinical recommendations of the International Society for Bipolar Disorders (ISBD) for the use of antidepressants in bipolar disorder

8.2.8. International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017)

8.3. Bipolar Disorder Guidelines Comparison

9. Epidemiology and patient population

9.1. Main conclusions

9.2. Epidemiology of bipolar depression

9.3. Epidemiological scenario: 7 MM

9.3.1. Total number of prevalent cases diagnosed with bipolar depression

9.3.2. Prevalent cases diagnosed by type of bipolar depression

9.3.3. Prevalent cases diagnosed by severity of bipolar depression

9.3.4. Total number of treated cases of bipolar depression

10. United States

11. EU-5

11.1. Germany

11.2. France

11.3. Italy

11.4. Spain

11.5. The United Kingdom

12. Japan

13. Patient journey

14. Main endpoints for clinical trials in bipolar depression

15. Marketed therapies

15.1. Vraylar (Cariprazine): Allergan (AbbVie) / Gedeon Richter

15.2. Latuda (lurasidone hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

16. Emerging therapies

16.1. Caplyta (ITI-007; Lumateperone): Intra-Cellular Therapies

16.2. NRX-100 / NRX-101: NeuroRx

16.3. SEP-4199: Sunovion (Sumitomo Dainippon Pharma)

16.4. Rexulti / Rxulti (Brexpiprazole): Lundbeck / Otsuka Pharmaceutical

16.5. Falkieri (Esketamine): Celon Pharma

16.6. COMP 360 (Psilocybin): COMPASS routes

17. Bipolar depression: 7 major market analyzes

17.1. Main conclusions

17.2. Market outlook

17.3. Market size of 7MM

17.3.1. Total Bipolar Depression Market Size in 7MM

17.3.2. Bipolar Depression Therapy Market Size in 7MM

18. The size of the United States market

18.1. Total size of the bipolar depression market in the United States

18.2. US Bipolar Depression Therapies Market Size

19. EU-5 market size

19.1. Germany

19.2. France

19.3. Italy

19.4. Spain

19.5. The United Kingdom

20. Japan

21. Market access and reimbursement

21.1. Top HTA Decisions for Bipolar Depression

21.2. Patient access programs

22. Market drivers

23. Market barriers

24. SWOT analysis

25. Unmet needs

26. Annex

Companies mentioned

  • Allergan (AbbVie) / Gedeon Richter
  • Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
  • Intracellular therapies
  • NeuroRx
  • Sunovion (Sumitomo Dainippon Pharma)
  • Lundbeck / Otsuka Pharmaceuticals
  • Celon Pharma
  • COMPAS course

For more information on this report, visit https://www.researchandmarkets.com/r/q70yb8

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210803005596/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Director

[email protected]

For EST office hours, call 1-917-300-0470

For USA / CAN call toll free 1-800-526-8630

For GMT office hours, call + 353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MENTAL HEALTH

SOURCE: Research and markets

Copyright Business Wire 2021.

PUB: 08/03/21 07:29 / DISC: 08/03/2021 07:29

http://www.businesswire.com/news/home/20210803005596/en

Comments are closed.